Condition

Disseminated Neuroblastoma

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 7 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials7
Recruiting0
Common interventions12
Lead sponsors shown6
Advertisement

Clinical trials

7 shown
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell TransplantNCT01558778 · 2012-05-01
WITHDRAWN
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile NeutropeniaNCT01484015 · 2011-02-01
COMPLETED
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron OverloadNCT01159067 · 2010-07-01
TERMINATED
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell TransplantNCT00795769 · 2008-08-08
COMPLETED
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell TransplantNCT00408681 · 2006-06-01
COMPLETED
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell TransplantNCT00309907 · 2006-04-01
COMPLETED
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerNCT00060372 · 2003-04-01
COMPLETED

Trial status mix

COMPLETED5
TERMINATED1
WITHDRAWN1

Phase mix

PHASE23
NA2
PHASE12

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.